APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell Line Development CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cell Line Development CDMO Market Outlook and Growth Opportunities 2026

5 June 2026212 pages

Choose your research edition.

Industry ResearchCell Line Development CDMO Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell Line Development CDMO Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Cell Line Development CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell Line Development CDMO Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell Line Development CDMO Market Analysis and Forecast 2026-2032185 pages · $4,950 USD

Market perspective

The global Cell Line Development CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cell Line Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cell Line Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cell Line Development CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cell Line Development CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cell Line Development CDMO market include Lonza, Samsung Biologics, AGC Biologics, ProBio CDMO, Creative Biolabs, ProBioGen, InvivoGen, Eurofins Discovery and Innoprot, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cell Line Development CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cell Line Development CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cell Line Development CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cell Line Development CDMO market.

Cell Line Development CDMO Segment by Company

Lonza

Samsung Biologics

AGC Biologics

ProBio CDMO

Creative Biolabs

ProBioGen

InvivoGen

Eurofins Discovery

Innoprot

AcceGen

WuXi Biologics

GenScript

Pharmaron

Bio-Inno

Dingkang Biotech

FUJIFILM

JCR Pharmaceuticals

Sartorius

Oxford BioMedica

Cobra Biologics

Evotec

Catalent

Thermo Fisher Scientific

Cytiva

Charles River Laboratories

Abzena

Shilpa Biologicals

Teijin

Cell Line Development CDMO Segment by Type

CHO Cell Line

HEK293 Cell Line

Others

Cell Line Development CDMO Segment by Application

Monoclonal Antibodies

Bispecific/Multispecific Antibodies

Recombinant Proteins/Enzymes

Gene Therapy Vectors

Viral Vaccines

Others

Cell Line Development CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cell Line Development CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cell Line Development CDMO key companies, revenue, market share, and recent developments.

3. To split the Cell Line Development CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cell Line Development CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cell Line Development CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Cell Line Development CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Line Development CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell Line Development CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Line Development CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cell Line Development CDMO industry.

Chapter 3: Detailed analysis of Cell Line Development CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cell Line Development CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cell Line Development CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cell Line Development CDMO Industry Trends Table 2. Cell Line Development CDMO Industry Drivers Table 3. Cell Line Development CDMO Industry Opportunities and Challenges Table 4. Cell Line Development CDMO Industry Restraints Table 5. Global Cell Line Development CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cell Line Development CDMO Revenue Share by Company (2021-2026) Table 7. Global Cell Line Development CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cell Line Development CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Cell Line Development CDMO Company, Product Type & Application Table 10. Global Cell Line Development CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cell Line Development CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of CHO Cell Line Table 15. Significant Companies of HEK293 Cell Line Table 16. Significant Companies of Others Table 17. Global Cell Line Development CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Cell Line Development CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Cell Line Development CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Cell Line Development CDMO Sales Value Share by Type (2021-2026) Table 21. Global Cell Line Development CDMO Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Monoclonal Antibodies Table 23. Significant Companies of Bispecific/Multispecific Antibodies Table 24. Significant Companies of Recombinant Proteins/Enzymes Table 25. Significant Companies of Gene Therapy Vectors Table 26. Significant Companies of Viral Vaccines Table 27. Significant Companies of Others Table 28. Global Cell Line Development CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Cell Line Development CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Cell Line Development CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Cell Line Development CDMO Sales Value Share by Application (2021-2026) Table 32. Global Cell Line Development CDMO Sales Value Share by Application (2027-2032) Table 33. Global Cell Line Development CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Cell Line Development CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Cell Line Development CDMO Sales Value Share by Region (2021-2026) Table 36. Global Cell Line Development CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Cell Line Development CDMO Sales Value Share by Region (2027-2032) Table 38. Global Cell Line Development CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Cell Line Development CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Cell Line Development CDMO Sales Value Market Share by Country (2021-2026) Table 41. Global Cell Line Development CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Cell Line Development CDMO Sales Value Market Share by Country (2027-2032) Table 43. Lonza Company Information Table 44. Lonza Business Overview Table 45. Lonza Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Lonza Cell Line Development CDMO Product Portfolio Table 47. Lonza Recent Development Table 48. Samsung Biologics Company Information Table 49. Samsung Biologics Business Overview Table 50. Samsung Biologics Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Samsung Biologics Cell Line Development CDMO Product Portfolio Table 52. Samsung Biologics Recent Development Table 53. AGC Biologics Company Information Table 54. AGC Biologics Business Overview Table 55. AGC Biologics Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. AGC Biologics Cell Line Development CDMO Product Portfolio Table 57. AGC Biologics Recent Development Table 58. ProBio CDMO Company Information Table 59. ProBio CDMO Business Overview Table 60. ProBio CDMO Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. ProBio CDMO Cell Line Development CDMO Product Portfolio Table 62. ProBio CDMO Recent Development Table 63. Creative Biolabs Company Information Table 64. Creative Biolabs Business Overview Table 65. Creative Biolabs Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Creative Biolabs Cell Line Development CDMO Product Portfolio Table 67. Creative Biolabs Recent Development Table 68. ProBioGen Company Information Table 69. ProBioGen Business Overview Table 70. ProBioGen Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. ProBioGen Cell Line Development CDMO Product Portfolio Table 72. ProBioGen Recent Development Table 73. InvivoGen Company Information Table 74. InvivoGen Business Overview Table 75. InvivoGen Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. InvivoGen Cell Line Development CDMO Product Portfolio Table 77. InvivoGen Recent Development Table 78. Eurofins Discovery Company Information Table 79. Eurofins Discovery Business Overview Table 80. Eurofins Discovery Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Eurofins Discovery Cell Line Development CDMO Product Portfolio Table 82. Eurofins Discovery Recent Development Table 83. Innoprot Company Information Table 84. Innoprot Business Overview Table 85. Innoprot Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Innoprot Cell Line Development CDMO Product Portfolio Table 87. Innoprot Recent Development Table 88. AcceGen Company Information Table 89. AcceGen Business Overview Table 90. AcceGen Cell Line Development CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. AcceGen Cell Line Development CDMO Product Portfolio Table 92. AcceGen Recent Development Table 93. WuXi Biologics Company Information Table 94. WuXi Biologics Business Overview Table 95. WuXi Biologics Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. WuXi Biologics Cell Line Development CDMO Product Portfolio Table 97. WuXi Biologics Recent Development Table 98. GenScript Company Information Table 99. GenScript Business Overview Table 100. GenScript Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. GenScript Cell Line Development CDMO Product Portfolio Table 102. GenScript Recent Development Table 103. Pharmaron Company Information Table 104. Pharmaron Business Overview Table 105. Pharmaron Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Pharmaron Cell Line Development CDMO Product Portfolio Table 107. Pharmaron Recent Development Table 108. Bio-Inno Company Information Table 109. Bio-Inno Business Overview Table 110. Bio-Inno Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Bio-Inno Cell Line Development CDMO Product Portfolio Table 112. Bio-Inno Recent Development Table 113. Dingkang Biotech Company Information Table 114. Dingkang Biotech Business Overview Table 115. Dingkang Biotech Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Dingkang Biotech Cell Line Development CDMO Product Portfolio Table 117. Dingkang Biotech Recent Development Table 118. FUJIFILM Company Information Table 119. FUJIFILM Business Overview Table 120. FUJIFILM Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. FUJIFILM Cell Line Development CDMO Product Portfolio Table 122. FUJIFILM Recent Development Table 123. JCR Pharmaceuticals Company Information Table 124. JCR Pharmaceuticals Business Overview Table 125. JCR Pharmaceuticals Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. JCR Pharmaceuticals Cell Line Development CDMO Product Portfolio Table 127. JCR Pharmaceuticals Recent Development Table 128. Sartorius Company Information Table 129. Sartorius Business Overview Table 130. Sartorius Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Sartorius Cell Line Development CDMO Product Portfolio Table 132. Sartorius Recent Development Table 133. Oxford BioMedica Company Information Table 134. Oxford BioMedica Business Overview Table 135. Oxford BioMedica Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Oxford BioMedica Cell Line Development CDMO Product Portfolio Table 137. Oxford BioMedica Recent Development Table 138. Cobra Biologics Company Information Table 139. Cobra Biologics Business Overview Table 140. Cobra Biologics Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Cobra Biologics Cell Line Development CDMO Product Portfolio Table 142. Cobra Biologics Recent Development Table 143. Evotec Company Information Table 144. Evotec Business Overview Table 145. Evotec Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Evotec Cell Line Development CDMO Product Portfolio Table 147. Evotec Recent Development Table 148. Catalent Company Information Table 149. Catalent Business Overview Table 150. Catalent Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Catalent Cell Line Development CDMO Product Portfolio Table 152. Catalent Recent Development Table 153. Thermo Fisher Scientific Company Information Table 154. Thermo Fisher Scientific Business Overview Table 155. Thermo Fisher Scientific Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Thermo Fisher Scientific Cell Line Development CDMO Product Portfolio Table 157. Thermo Fisher Scientific Recent Development Table 158. Cytiva Company Information Table 159. Cytiva Business Overview Table 160. Cytiva Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Cytiva Cell Line Development CDMO Product Portfolio Table 162. Cytiva Recent Development Table 163. Charles River Laboratories Company Information Table 164. Charles River Laboratories Business Overview Table 165. Charles River Laboratories Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. Charles River Laboratories Cell Line Development CDMO Product Portfolio Table 167. Charles River Laboratories Recent Development Table 168. Abzena Company Information Table 169. Abzena Business Overview Table 170. Abzena Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 171. Abzena Cell Line Development CDMO Product Portfolio Table 172. Abzena Recent Development Table 173. Shilpa Biologicals Company Information Table 174. Shilpa Biologicals Business Overview Table 175. Shilpa Biologicals Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 176. Shilpa Biologicals Cell Line Development CDMO Product Portfolio Table 177. Shilpa Biologicals Recent Development Table 178. Teijin Company Information Table 179. Teijin Business Overview Table 180. Teijin Cell Line Development CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 181. Teijin Cell Line Development CDMO Product Portfolio Table 182. Teijin Recent Development Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Cell Line Development CDMO Product Image Figure 2. Global Cell Line Development CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell Line Development CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Cell Line Development CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. CHO Cell Line Image Figure 8. HEK293 Cell Line Image Figure 9. Others Image Figure 10. Global Cell Line Development CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Cell Line Development CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Cell Line Development CDMO Sales Value Share by Type (2021-2032) Figure 13. Monoclonal Antibodies Image Figure 14. Bispecific/Multispecific Antibodies Image Figure 15. Recombinant Proteins/Enzymes Image Figure 16. Gene Therapy Vectors Image Figure 17. Viral Vaccines Image Figure 18. Others Image Figure 19. Global Cell Line Development CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Cell Line Development CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Cell Line Development CDMO Sales Value Share by Application (2021-2032) Figure 22. Global Cell Line Development CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Cell Line Development CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Cell Line Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 25. North America Cell Line Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Cell Line Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Cell Line Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Cell Line Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Cell Line Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Cell Line Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 31. South America Cell Line Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Cell Line Development CDMO Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Cell Line Development CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Cell Line Development CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • CHO Cell Line
  • HEK293 Cell Line
  • Others
Applications
  • Monoclonal Antibodies
  • Bispecific/Multispecific Antibodies
  • Recombinant Proteins/Enzymes
  • Gene Therapy Vectors
  • Viral Vaccines
  • Others
Companies covered
  • Lonza
  • Samsung Biologics
  • AGC Biologics
  • ProBio CDMO
  • Creative Biolabs
  • ProBioGen
  • InvivoGen
  • Eurofins Discovery
  • Innoprot
  • AcceGen
  • WuXi Biologics
  • GenScript
  • Pharmaron
  • Bio-Inno
  • Dingkang Biotech
  • FUJIFILM
  • JCR Pharmaceuticals
  • Sartorius
  • Oxford BioMedica
  • Cobra Biologics
  • Evotec
  • Catalent
  • Thermo Fisher Scientific
  • Cytiva
  • Charles River Laboratories
  • Abzena
  • Shilpa Biologicals
  • Teijin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cell Line Development CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cell Line Development CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cell Line Development CDMO Market Dynamics
  1. 2.1 Cell Line Development CDMO Industry Trends
  2. 2.2 Cell Line Development CDMO Industry Drivers
  3. 2.3 Cell Line Development CDMO Industry Opportunities and Challenges
  4. 2.4 Cell Line Development CDMO Industry Restraints
3 Cell Line Development CDMO Market by Company
  1. 3.1 Global Cell Line Development CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Cell Line Development CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Cell Line Development CDMO Company Ranking (2024-2026)
  4. 3.4 Global Cell Line Development CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Cell Line Development CDMO Company Product Type and Application
  6. 3.6 Global Cell Line Development CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cell Line Development CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cell Line Development CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cell Line Development CDMO Market by Type
  1. 4.1 Cell Line Development CDMO Type Introduction
  2. 4.1.1 CHO Cell Line
  3. 4.1.2 HEK293 Cell Line
  4. 4.1.3 Others
  5. 4.2 Global Cell Line Development CDMO Sales Value by Type
  6. 4.2.1 Global Cell Line Development CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Cell Line Development CDMO Sales Value by Type (2021-2032)
  8. 4.2.3 Global Cell Line Development CDMO Sales Value Share by Type (2021-2032)
5 Cell Line Development CDMO Market by Application
  1. 5.1 Cell Line Development CDMO Application Introduction
  2. 5.1.1 Monoclonal Antibodies
  3. 5.1.2 Bispecific/Multispecific Antibodies
  4. 5.1.3 Recombinant Proteins/Enzymes
  5. 5.1.4 Gene Therapy Vectors
  6. 5.1.5 Viral Vaccines
  7. 5.1.6 Others
  8. 5.2 Global Cell Line Development CDMO Sales Value by Application
  9. 5.2.1 Global Cell Line Development CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Cell Line Development CDMO Sales Value by Application (2021-2032)
  11. 5.2.3 Global Cell Line Development CDMO Sales Value Share by Application (2021-2032)
6 Cell Line Development CDMO Regional Value Analysis
  1. 6.1 Global Cell Line Development CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cell Line Development CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cell Line Development CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cell Line Development CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cell Line Development CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Cell Line Development CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cell Line Development CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Cell Line Development CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cell Line Development CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cell Line Development CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cell Line Development CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Cell Line Development CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cell Line Development CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cell Line Development CDMO Sales Value Share by Country, 2025 VS 2032
7 Cell Line Development CDMO Country-level Value Analysis
  1. 7.1 Global Cell Line Development CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cell Line Development CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cell Line Development CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cell Line Development CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cell Line Development CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cell Line Development CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cell Line Development CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Lonza
  2. 8.1.1 Lonza Company Information
  3. 8.1.2 Lonza Business Overview
  4. 8.1.3 Lonza Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lonza Cell Line Development CDMO Product Portfolio
  6. 8.1.5 Lonza Recent Developments
  7. 8.2 Samsung Biologics
  8. 8.2.1 Samsung Biologics Company Information
  9. 8.2.2 Samsung Biologics Business Overview
  10. 8.2.3 Samsung Biologics Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Samsung Biologics Cell Line Development CDMO Product Portfolio
  12. 8.2.5 Samsung Biologics Recent Developments
  13. 8.3 AGC Biologics
  14. 8.3.1 AGC Biologics Company Information
  15. 8.3.2 AGC Biologics Business Overview
  16. 8.3.3 AGC Biologics Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AGC Biologics Cell Line Development CDMO Product Portfolio
  18. 8.3.5 AGC Biologics Recent Developments
  19. 8.4 ProBio CDMO
  20. 8.4.1 ProBio CDMO Company Information
  21. 8.4.2 ProBio CDMO Business Overview
  22. 8.4.3 ProBio CDMO Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ProBio CDMO Cell Line Development CDMO Product Portfolio
  24. 8.4.5 ProBio CDMO Recent Developments
  25. 8.5 Creative Biolabs
  26. 8.5.1 Creative Biolabs Company Information
  27. 8.5.2 Creative Biolabs Business Overview
  28. 8.5.3 Creative Biolabs Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Creative Biolabs Cell Line Development CDMO Product Portfolio
  30. 8.5.5 Creative Biolabs Recent Developments
  31. 8.6 ProBioGen
  32. 8.6.1 ProBioGen Company Information
  33. 8.6.2 ProBioGen Business Overview
  34. 8.6.3 ProBioGen Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProBioGen Cell Line Development CDMO Product Portfolio
  36. 8.6.5 ProBioGen Recent Developments
  37. 8.7 InvivoGen
  38. 8.7.1 InvivoGen Company Information
  39. 8.7.2 InvivoGen Business Overview
  40. 8.7.3 InvivoGen Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 InvivoGen Cell Line Development CDMO Product Portfolio
  42. 8.7.5 InvivoGen Recent Developments
  43. 8.8 Eurofins Discovery
  44. 8.8.1 Eurofins Discovery Company Information
  45. 8.8.2 Eurofins Discovery Business Overview
  46. 8.8.3 Eurofins Discovery Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eurofins Discovery Cell Line Development CDMO Product Portfolio
  48. 8.8.5 Eurofins Discovery Recent Developments
  49. 8.9 Innoprot
  50. 8.9.1 Innoprot Company Information
  51. 8.9.2 Innoprot Business Overview
  52. 8.9.3 Innoprot Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Innoprot Cell Line Development CDMO Product Portfolio
  54. 8.9.5 Innoprot Recent Developments
  55. 8.10 AcceGen
  56. 8.10.1 AcceGen Company Information
  57. 8.10.2 AcceGen Business Overview
  58. 8.10.3 AcceGen Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AcceGen Cell Line Development CDMO Product Portfolio
  60. 8.10.5 AcceGen Recent Developments
  61. 8.11 WuXi Biologics
  62. 8.11.1 WuXi Biologics Company Information
  63. 8.11.2 WuXi Biologics Business Overview
  64. 8.11.3 WuXi Biologics Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 WuXi Biologics Cell Line Development CDMO Product Portfolio
  66. 8.11.5 WuXi Biologics Recent Developments
  67. 8.12 GenScript
  68. 8.12.1 GenScript Company Information
  69. 8.12.2 GenScript Business Overview
  70. 8.12.3 GenScript Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GenScript Cell Line Development CDMO Product Portfolio
  72. 8.12.5 GenScript Recent Developments
  73. 8.13 Pharmaron
  74. 8.13.1 Pharmaron Company Information
  75. 8.13.2 Pharmaron Business Overview
  76. 8.13.3 Pharmaron Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pharmaron Cell Line Development CDMO Product Portfolio
  78. 8.13.5 Pharmaron Recent Developments
  79. 8.14 Bio-Inno
  80. 8.14.1 Bio-Inno Company Information
  81. 8.14.2 Bio-Inno Business Overview
  82. 8.14.3 Bio-Inno Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bio-Inno Cell Line Development CDMO Product Portfolio
  84. 8.14.5 Bio-Inno Recent Developments
  85. 8.15 Dingkang Biotech
  86. 8.15.1 Dingkang Biotech Company Information
  87. 8.15.2 Dingkang Biotech Business Overview
  88. 8.15.3 Dingkang Biotech Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dingkang Biotech Cell Line Development CDMO Product Portfolio
  90. 8.15.5 Dingkang Biotech Recent Developments
  91. 8.16 FUJIFILM
  92. 8.16.1 FUJIFILM Company Information
  93. 8.16.2 FUJIFILM Business Overview
  94. 8.16.3 FUJIFILM Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  95. 8.16.4 FUJIFILM Cell Line Development CDMO Product Portfolio
  96. 8.16.5 FUJIFILM Recent Developments
  97. 8.17 JCR Pharmaceuticals
  98. 8.17.1 JCR Pharmaceuticals Company Information
  99. 8.17.2 JCR Pharmaceuticals Business Overview
  100. 8.17.3 JCR Pharmaceuticals Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  101. 8.17.4 JCR Pharmaceuticals Cell Line Development CDMO Product Portfolio
  102. 8.17.5 JCR Pharmaceuticals Recent Developments
  103. 8.18 Sartorius
  104. 8.18.1 Sartorius Company Information
  105. 8.18.2 Sartorius Business Overview
  106. 8.18.3 Sartorius Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Sartorius Cell Line Development CDMO Product Portfolio
  108. 8.18.5 Sartorius Recent Developments
  109. 8.19 Oxford BioMedica
  110. 8.19.1 Oxford BioMedica Company Information
  111. 8.19.2 Oxford BioMedica Business Overview
  112. 8.19.3 Oxford BioMedica Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Oxford BioMedica Cell Line Development CDMO Product Portfolio
  114. 8.19.5 Oxford BioMedica Recent Developments
  115. 8.20 Cobra Biologics
  116. 8.20.1 Cobra Biologics Company Information
  117. 8.20.2 Cobra Biologics Business Overview
  118. 8.20.3 Cobra Biologics Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cobra Biologics Cell Line Development CDMO Product Portfolio
  120. 8.20.5 Cobra Biologics Recent Developments
  121. 8.21 Evotec
  122. 8.21.1 Evotec Company Information
  123. 8.21.2 Evotec Business Overview
  124. 8.21.3 Evotec Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Evotec Cell Line Development CDMO Product Portfolio
  126. 8.21.5 Evotec Recent Developments
  127. 8.22 Catalent
  128. 8.22.1 Catalent Company Information
  129. 8.22.2 Catalent Business Overview
  130. 8.22.3 Catalent Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Catalent Cell Line Development CDMO Product Portfolio
  132. 8.22.5 Catalent Recent Developments
  133. 8.23 Thermo Fisher Scientific
  134. 8.23.1 Thermo Fisher Scientific Company Information
  135. 8.23.2 Thermo Fisher Scientific Business Overview
  136. 8.23.3 Thermo Fisher Scientific Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Thermo Fisher Scientific Cell Line Development CDMO Product Portfolio
  138. 8.23.5 Thermo Fisher Scientific Recent Developments
  139. 8.24 Cytiva
  140. 8.24.1 Cytiva Company Information
  141. 8.24.2 Cytiva Business Overview
  142. 8.24.3 Cytiva Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Cytiva Cell Line Development CDMO Product Portfolio
  144. 8.24.5 Cytiva Recent Developments
  145. 8.25 Charles River Laboratories
  146. 8.25.1 Charles River Laboratories Company Information
  147. 8.25.2 Charles River Laboratories Business Overview
  148. 8.25.3 Charles River Laboratories Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Charles River Laboratories Cell Line Development CDMO Product Portfolio
  150. 8.25.5 Charles River Laboratories Recent Developments
  151. 8.26 Abzena
  152. 8.26.1 Abzena Company Information
  153. 8.26.2 Abzena Business Overview
  154. 8.26.3 Abzena Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Abzena Cell Line Development CDMO Product Portfolio
  156. 8.26.5 Abzena Recent Developments
  157. 8.27 Shilpa Biologicals
  158. 8.27.1 Shilpa Biologicals Company Information
  159. 8.27.2 Shilpa Biologicals Business Overview
  160. 8.27.3 Shilpa Biologicals Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Shilpa Biologicals Cell Line Development CDMO Product Portfolio
  162. 8.27.5 Shilpa Biologicals Recent Developments
  163. 8.28 Teijin
  164. 8.28.1 Teijin Company Information
  165. 8.28.2 Teijin Business Overview
  166. 8.28.3 Teijin Cell Line Development CDMO Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Teijin Cell Line Development CDMO Product Portfolio
  168. 8.28.5 Teijin Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst